If you've been comparing FIP oral treatments, you may have noticed something that looks like a discrepancy: CureFIP Oral Capsules contain less GS-441524 per capsule than some competing products. We want to address this head-on — because the question is entirely reasonable, and the answer reveals something important about where oral FIP treatment is heading, and what responsible formulation looks like in response.
The Shift to Oral Treatment Created a New Problem
GS-441524 changed everything for FIP. As a nucleoside analog, it mimics the building blocks of RNA and gets incorporated into the FIP virus's replication machinery — jamming the process and preventing the virus from reproducing. When daily injections were the primary delivery method, outcomes were strong and resistance was rarely a concern.
Then oral treatment became the dominant format. Understandably so — the convenience is real, compliance is easier, and the cat suffers less. But oral delivery introduced something injections largely avoided: a sustained, predictable, daily exposure to a single antiviral compound across twelve or more weeks of treatment.
That is the ideal environment for a virus to learn. RNA viruses replicate fast, mutate constantly, and under sustained selective pressure from one mechanism, they will eventually find a way around it. The longer the treatment window, the more opportunities the virus gets. The more monotherapy dominates the market, the more cats cycle through it — and the broader the pool in which resistance strains can emerge and spread.
This is not a theoretical concern. Dr. Niels C. Pedersen of UC Davis — the researcher who established GS-441524 as the first effective FIP treatment — documented confirmed resistance cases in a 2021 paper co-authored with Nicole Jacque. His conclusion was unambiguous: resistance was real, it was accumulating, and it was especially prevalent in neurological FIP cases where treatment runs longest.
More Milligrams Is Not a Strategy
The market's instinctive answer to resistance has been to increase the dose. Stack more GS-441524 into each capsule. Put a bigger number on the label. The implicit promise: if resistance is a risk, higher concentration will outrun it.
Pedersen addressed this directly in his paper and dismissed it as an incomplete solution. He acknowledged that dose escalation can overcome partial resistance in some cats, but wrote plainly that resistance may become "complete or so high that increasing the dose is no longer effective."
At that threshold, a higher-milligram capsule of the same compound offers nothing that a standard-milligram capsule of the same compound does not. You are paying more for a formulation that has already hit its ceiling.
The solution Pedersen identified was not a larger dose. It was a different mechanism.
What a Second Mechanism Actually Does
CureFIP Oral Capsules combine GS-441524 with EIDD-1931 — the active metabolite of molnupiravir. These two compounds do not work the same way. They do not even attack the same point in the viral lifecycle.
Acts as a non-obligate RNA chain terminator. It mimics viral RNA building blocks and, once incorporated, blocks the extension of the RNA strand — stopping replication before a complete copy of the virus can be made. To survive this, the virus must mutate its RNA-dependent RNA polymerase.
Does not stop replication — it corrupts it. EIDD-1931 is incorporated into viral RNA during copying and floods the output with genetic errors at a rate the virus cannot sustain viability. Pedersen's paper notes it "has been shown to function as an RNA mutagen causing several defects in the viral genome" and that its resistance profile is distinct from GS-441524's.
The result of combining these two mechanisms is not merely additive antiviral pressure. It is a structural closing of the escape route. For the FIP virus to develop resistance against this combination, it would need to simultaneously evolve around chain termination and error induction — two independent adaptive challenges at two separate points in its lifecycle. The probability of that happening collapses.
This is the same logic that transformed HIV from a death sentence into a manageable condition. Not a more powerful single drug — a second drug that closed the door the first one left open. Pedersen cited this precedent explicitly. Combination antiviral therapy is not a new idea in medicine. It is a proven one. The FIP treatment market has been slow to follow it.
Why the Milligram Comparison Misleads
When a cat owner compares two capsules and sees that one has more GS-441524, the intuition is natural: more active ingredient means more treatment. That logic holds when both products are doing the same thing. It breaks down when one product is doing two things.
| What you're comparing | Pure GS-441524 monotherapy | CureFIP Oral Capsules |
|---|---|---|
| Active compounds | GS-441524 only | GS-441524 + EIDD-1931 |
| Mechanisms of action | Chain termination | Chain termination + lethal mutagenesis |
| Resistance vulnerability | Single point of failure | Dual adaptive barrier |
| Dose escalation ceiling | Exists — and Pedersen documented it | Shifted by the second mechanism |
| What the mg count tells you | Full picture of antiviral load | Partial picture — EIDD-1931 not counted |
The GS-441524 milligram in our capsule is lower because it does not need to carry the entire antiviral burden alone. EIDD-1931 is doing work alongside it — work that does not appear in a milligram comparison because it is a different molecule entirely. Comparing only the GS-441524 content of our capsule to a competitor's is like comparing the horsepower of one engine in a two-engine aircraft to the total output of a single-engine plane and concluding the second aircraft is more powerful.
The Honest Reason Other Products Don't Do This
Formulating a dual-compound capsule is harder than formulating a single-compound one. It requires compatibility testing between two active ingredients, stability data across the combined formulation, and a more rigorous manufacturing process. It is easier — and commercially simpler — to increase the milligrams of one proven compound and market the number.
We are not saying every company that sells pure GS-441524 capsules is being cynical. Some entered the market before the resistance picture was as clear as it is now. But the Pedersen paper was published in November 2021. The resistance data it cites covers three years of confirmed cases before that. Companies formulating FIP oral treatments in 2024 and 2025 are doing so with that information available to them.
The decision to remain on monotherapy at this point is a formulation choice. It is one worth understanding before you make a treatment choice.
What This Means for Your Cat
If your cat is beginning FIP treatment, the most important question is not which capsule has the most milligrams of GS-441524. It is which capsule gives the virus the fewest opportunities to adapt and survive a 12-week treatment course.
CureFIP Oral Capsules were formulated with that principle in mind — not to compete on a number, but to close the gap that the number alone cannot close. The cats going through oral FIP treatment right now are doing so over weeks and months. The formulation they are on matters for the entire duration of that time. We built ours to hold up across all of it.
